Paradigm Biopharmaceuticals (ASX: PAR) has completed enrolment in its global pivotal PARA_OA_012 Phase 3 study of Zilosul for knee osteoarthritis pain, with 538 participants commencing treatment across 65 clinical sites. Database lock and data preparation for a pre-specified interim analysis are expected during August, followed by an independent Data Safety Monitoring Board (DSMB) review targeted for September 2026. Paradigm is now concentrating clinical operations on treatment completion, follow-up assessments, safety monitoring, data management, and maintaining protocol integrity ahead of the Interim Analysis. The dual clinical research organisation model remains in place, with Advanced Clinical managing Australia and the United States and Nordic Bioscience Clinical Development supporting Hong Kong and Moldova. Paradigm expects its available capital to support the Interim Analysis, Phase 3 top-line results and continuing regulatory, New Drug Application, manufacturing, and commercial-readiness work.